26 completed, 13 active not recruiting, 12 recruiting, 2 terminated. 33 Phase 1, 22 Phase 2, 5 Phase 3, 1 Early Phase 1.
Follow Arcus Biosciences, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function Casdatifan - Healthy Participants, Hepatic Impairment | Phase 1 | Recruiting | Arcus Biosciences, Inc. | 16 | 2026-08-14 | 2026-09-04 |
| A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants AB102, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Arcus Biosciences, Inc. | 130 | 2026-07-09 | 2026-08-25 |
| A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants Casdatifan - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 24 | 2026-05-29 | 2026-08-13 |
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-09 | 2026-03-20 |
| Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) Quemliclustat - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 8 | 2026-02-03 | 2026-05-01 |
| Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) - Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-02-01 | 2025-12-26 | |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Casdatifan, Cabozantinib, Placebo - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Arcus Biosciences, Inc. | 720 | 2025-09-08 | 2026-10-26 |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC Volrustomig, Casdatifan - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Active not recruiting | AstraZeneca | 9 | 2025-07-28 | 2026-08-03 |
| Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) Casdatifan, Itraconazole, Phenytoin - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 14 | 2025-05-02 | 2025-11-13 |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Domvanalimab, Zimberelimab, Paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Gilead Sciences | 39 | 2025-02-18 | 2026-09-03 |
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Quemliclustat, Placebo, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Active not recruiting | Arcus Biosciences, Inc. | 610 | 2024-12-13 | 2026-09-29 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) zanzalintinib, AB521, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Phase 1 | Terminated | Exelixis | 25 | 2024-01-25 | 2025-06-12 |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies AB801, Docetaxel - Advanced Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 29 | 2024-01-19 | 2026-10-09 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers AB801, Placebo - Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 32 | 2023-10-16 | 2024-08-28 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers AB598, Zimberelimab, Fluorouracil - Advanced Cancer, Advanced Malignancies | Phase 1 | Active not recruiting | Arcus Biosciences, Inc. | 40 | 2023-10-13 | 2026-09-29 |
Showing 20 of 56. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Carcinoma, Renal Cell (6) · Stomach Neoplasms (5) · Kidney Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Melanoma (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Cholangiocarcinoma (2) · Clear-cell metastatic renal cell carcinoma (2) · Esophageal Neoplasms (2)
zimberelimab (32) · quemliclustat (14) · Carboplatin (5) · 130-nm albumin-bound paclitaxel (4) · Cisplatin (4) · Docetaxel (4) · Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (4) · Paclitaxel (4) · Pemetrexed (4) · pembrolizumab (4) · Gemcitabine (3) · Nivolumab (3) · Itraconazole (2)
United States (48) · Australia (15) · South Korea (14) · Spain (10) · United Kingdom (10) · Canada (9) · France (9) · Taiwan (9) · Italy (8) · Hong Kong (6) · Japan (5) · Netherlands (5) · Poland (5) · Turkey (Türkiye) (5) · Brazil (4)
Alexander Spira, MD, PhD (1) · Brian Rini (1) · Catherine S. Spina, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · David Hsieh, MD (1) · David Oh, MD, PhD (1) · Diwakar Davar, MD (1) · Encouse Golden, M.D., Ph.D. (1) · Gulam Manji, MD, PhD (1) · Hidehito Horinouchi, MD, PhD (1) · James Cleary, MD, PhD (1) · Jennifer Choe, MD, PhD (1) · Jinming Yu, MD, PhD (1)
PMID 31334635, PMID 40341124, PMID 40592848, PMID 41109921, PMID 41912809, PMID 42246926, PMID 42481461
2023 (1), R01CA266757 (1)